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Abstract
There is a small but growing body of literature regarding the predictive utility
of a Let-7 microRNA-binding-site polymorphism in the 30 -untranslated region
(UTR) of KRAS (KRAS-LCS6) for colorectal cancer outcome, although the
results are conflicting. We performed a review and meta-analysis in an attempt
to better clarify this relationship. A PubMed search was conducted to identify
all studies reporting on KRAS let-7 microRNA-binding site polymorphism
(LCS6; rs61764370) and colorectal cancer outcome. Hazard ratios (HR) and
corresponding 95% confidence intervals (CI) were extracted or estimated from
each manuscript. Log HRs and log CIs were combined across studies using the
inverse-variance weight to calculate fixed- and random-effects summary estimates and corresponding 95% CIs for overall and progression-free survival. We
did not observe any significant association between overall or progression-free
survival, neither when considering all colorectal cancer patients nor for subgroup analyses (metastatic, anti-EGFR [epidermal growth factor receptor] treatment, or KRAS wild type). There was substantial heterogeneity across studies,
overall and among subgroups analyzed. We have found no clear evidence to
support an association between the KRAS-LCS6 genotype and overall or progression-free survival among colorectal cancer patients, even after conducting
subgroup analyses by stage and anti-EGFR treatment status. This information
helps to clarify the confusing body of literature regarding the clinical implications of the KRAS-LCS6 genetic variant on colorectal cancer outcomes, indicating that it should not be used at the present time to personalize therapeutic
strategies (PROSPERO registration number: CRD42013005325).

Introduction
It is estimated that colorectal cancer was responsible for
over 50,000 deaths in the United States in 2013, making it
the second leading cause of cancer-related mortality [1].
Despite this, advances in treatment for colorectal cancer
have improved disease prognosis over the past decade.
Monoclonal antibody therapies that target epidermal
growth factor receptor (EGFR), including cetuximab (Erbitux, ImClone, LLC) and panitumumab (Vectibix, Amgen),
are becoming widely used approaches [2], particularly for
patients with chemorefractory metastatic disease [3].

Through clinical trials, several groups have observed that
colorectal cancer patients without somatic mutations in
KRAS benefit from anti-EGFR therapy relative to patients
harboring a somatic KRAS mutation [4–8]. However, only
about half of metastatic colorectal cancer patients with
wild-type KRAS tumors respond to anti-EGFR treatment
[9], indicating a need for additional biomarkers of
treatment response. Other prognostic markers have been
proposed, including BRAF V600E mutational status [10],
but they remain incomplete predictors [11], leaving behind
a void in precision medicine therapeutic strategies for
colorectal cancer that begs for improvement.

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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Beyond the use of KRAS mutation status to stratify
patients for therapy, normal genetic variation also may
contribute to the regulation of KRAS and potentially affect
response to therapy among patients with wild-type KRAS.
For instance, microRNA (miRNA) are known to bind conserved 30 -untranslated regions (UTRs) of genes to prevent
their translation, and a single-nucleotide polymorphism
(SNP) in the 30 UTR stemming from a T to G transversion
in the sixth let-7 complementary site of KRAS that affects
the binding of let-7 family miRNA and results in lower levels of KRAS expression has been described [12]. Since the
characterization of the KRAS miRNA-related SNP known
as KRAS-LCS6 (rs61764370), there have been a number of
studies on the relationship of its genotype with risk
[13–18] and prognosis [19–28] of several cancers, with
many such studies directed toward colorectal cancer outcome [19–26]. To date, studies reporting on the association
of KRAS-LCS6 genotype and colorectal cancer outcome
have presented conflicting and clinically confusing results,
with some presenting significant estimates with effects in
opposing directions. Here, we describe a review and metaanalysis of the relationship between KRAS-LCS6 genotype
with overall and disease-free survival among colorectal cancer patients in an effort to add clarity to the potential
implications, if any, of this functional genetic KRAS variant
on clinical management.

Methods
Study identification and selection
Studies reporting on the relationship between the KRAS
let-7 miRNA-binding-site polymorphism (KRAS-LCS6;
rs61764370) and colorectal cancer outcome were identified by entering the following search terms into PubMed
(http://www.ncbi.nlm.nih.gov/pubmed): (“let-7” OR let7
OR lcs6 OR rs61764370) AND (snp OR polymorphism OR
variant) AND (colon OR colorectal OR crc OR mcrc) published in the English language through 31 December 2013.
Studies were included if they reported on the KRAS-LCS6
polymorphism and overall or progression-free survival for
colorectal cancer patients. The literature was further scrutinized for relevant studies by cross-checking the references of all manuscripts identified through the PubMed
search. In the case of overlapping data sets between studies, the most inclusive was retained. This systematic
review and meta-analysis was prospectively registered with
the PROSPERO database [29] (CRD42013005325).

Data extraction
Initial eligibility was determined by screening the study
abstracts of articles returned in the PubMed search. Arti-
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cles that were not excluded during the preliminary screening step were examined in more depth by reading the
full-text to ensure that they met the inclusion criteria.
Study descriptors were derived from the full-text, including the country in which the study was conducted, treatment modalities, stage at diagnosis, primary outcomes,
years of recruitment, median age, proportion of male subjects, and races/ethnicities of the study subjects. Additionally, the number and frequency of KRAS-LCS6 TT versus
GT/TT genotype, hazard ratio (HR), and corresponding
95% confidence interval (CI) estimates (or information
allowing for the indirect estimation of the HR as
described in later sections) were extracted from the fulltext. In the absence of adequate information for estimation of a hazard ratio, all efforts were made to contact
the authors to obtain sufficient information, as described
below.

Survival curve estimation
Summary survival curves for overall and progression-free
survival were estimated by systematically parsing Kaplan–
Meier survival curves presented in each manuscript into
equal, prespecified, nonoverlapping time intervals (6month intervals for overall survival; 3-month intervals for
progression-free survival) and estimating the survival
probability for KRAS-LCS6 TT and TG/GG genotypes,
respectively, using the methods described by Parmar et al.
[30]. For estimation, censoring was assumed to be noninformative and to have occurred at a constant rate. The
number of patients censored at each time interval, Ci(ti),
si Þðtei tsi Þ
, where Ri is the
was estimated by Ci ðti Þ ¼ R2i ðt ðF
max tsi Þ

number at-risk, ts is the start of the interval, te is the end
of the interval, and Fmax is the maximum follow-up in
the study. At-risk patients during each interval were calculated as Ri(t) = Ri(ts)  Ci(t). Summary survival curves
were then generated by KRAS-LCS6 genotype (TT vs. TG/
GG) by taking a weighted average based on the number
of at-risk subjects for each respective study at each time
interval.

Summary hazard ratio estimates
Log HR and corresponding 95% CI for the association of
KRAS-LCS6 G allele carriers (*G) with overall and progression-free survival were extracted for each study by
cancer stage and treatment modality wherever possible.
When HR estimates were not provided, they were indipﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ 1
ORTT RG U ð1P2 Þ
,
rectly estimated by log d
HR ¼ ðOG EG Þ ¼
OR R
^
V

TT G
RTT þRG

where O is the total number of events between both
genotype groups, OG and EG represent the respective

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Identification

observed and expected events for G allele carriers, V^1 is the
estimated Mantel–Haenszel variance of the log-HR, RTT,
and RG, respectively, represent the total number of
patients with TT or *G genotype, p is the two-sided logrank P-value for a survival difference by KRAS-LCS6
genotype, and Φ is the cumulative-distribution function
for a standard normal distribution. Median survival time
is not considered suitable for HR estimation [31].
Log HRs and log CIs were combined across studies
using the inverse-variance weight to calculate fixed-effects
and random-effects summary estimates (DerSimonian
and Laird method) and corresponding 95% CIs [32]. In
the absence of between-study heterogeneity (Q-statistic
P > 0.05), fixed-effect estimates were reported to conserve
statistical power; otherwise random-effects were reported.
Meta-analyses were performed for the association of
KRAS-LCS6 *G genotype with overall survival for all
studies stratified by cancer stage. Two additional subgroup analyses were performed (1) restricted to metastatic
colorectal cancer stratified by treatment modality (antiEGFR vs. no anti-EGFR) and (2) restricted to KRAS
wild-type patients (i.e., without somatic KRAS mutation).
Progression-free survival was likewise stratified by treatment modality; a subgroup analysis of KRAS wild-type
patients was also performed. Heterogeneity was evaluated
quantitatively using the Q-statistic and I2 metric [33].
Risk of publication bias across studies was assessed using

12 records identified
through PubMed

the Egger test [34]; qualitative likelihood of the summary
estimate to be invalidated by bias was also considered.

Results
Study selection
The PubMed search returned 12 potential manuscripts
[19–26, 35–38], of which eight met the inclusion criteria
by reporting data on the association between the KRASLCS6 polymorphism and overall and/or progression-free
survival for colorectal cancer patients [19–26]. Two sets
of overlapping study populations were identified [19, 21,
25, 26] among the eight qualified studies, so the less
inclusive study for each overlapping was excluded accordingly [21, 25]. All of the remaining six studies [19, 20,
22–24, 26] reported overall survival and included a total
of 1672 patients, while four reported progression-free survival [19, 20, 23, 26] and included a total of 823 patients.
A flow diagram of the study identification and selection
process is presented in Figure 1. Two of the six eligible
studies presented results by stage at diagnosis [22, 24]
(the remaining four studies were restricted to advanced
stage metastatic cases) and thus were presented accordingly in the meta-analyses, for a total of nine data sets.
Three studies did not report HR [20, 23, 26], but presented the number of at-risk patients by KRAS-LCS6

0 additional records identified by
cross-checking references

4 manuscripts excluded

Screening

12 records screened

2 less-inclusive overlapping
manuscripts excluded

Eligibility

8 full-text articles
assessed for eligibility

Included

6 publications included in the
meta-analysis
2 studies did not assess
progression-free survival
6 studies for meta-analysis
of overall survival

4 studies for meta-analysis
of progression-free survival

Figure 1. Flow diagram of the study selection for inclusion in the meta-analysis.
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genotype and log-rank P-values for survival difference, so
additional information (total number of survival and progression events) was obtained through personal communications with the respective authors that allowed for
indirect estimation of the HR using the methods
described by Parmar et al. [30]. The stage-specific number of at-risk patients by KRAS-LCS6 genotype were
obtained for the study by Ryan et al. [22] via personal
communication to allow us to use their Kaplan–Meier
function for survival curve estimation.

Study characteristics
A description of the study characteristics for the six eligible studies [19, 20, 22–24, 26] is provided in Table 1. The
studies were similar in terms of median age but there was
considerable variability with respect to stage at diagnosis
and treatment modality. The studies differ by country of
origin and there was some variation in terms of racial/ethnic groups included, but the majority of the subjects
reported in the literature were white; the study by Ryan
et al. [22] was the only publication that contained an
appreciable number of non-white patients. Three of the
four studies reporting on metastatic colorectal cancer
involved only patients treated with anti-EGFR therapy
[19, 23, 26]. The study by Kjersem et al. [20] included
patients from a randomized clinical trial who were treated
with Nordic FLOX (bolus 5-fluorouracil/folinic acid and
oxaliplatin) either with or without anti-EGFR therapy and
did not present KRAS-LCS6 survival data by treatment
modality. However, we were able to obtain treatment-specific log-rank P-values and number of at-risk patients and
events to allow for estimation of the treatment-specific
HR through personal communications with the authors.
Of the four publications that specified treatment with
anti-EGFR therapy (cetuximab or panitumumab), all
patients included in the studies by Zhang et al. [26] and
Sebio et al. [23] were free of any somatic KRAS mutations, while 43% of the patients in Graziano et al. study
[19] and 39% of the patients in the Kjersem et al. study
[20] harbored a somatic KRAS mutation; the study by
Graziano et al. [19] additionally presented a subgroup
analysis of 63 KRAS wild-type patients. All of the 121
patients included in the survival analyses by Graziano
et al. [19] were free of the BRAF V600E mutation.

Meta-analyses
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(Fig. 2), although there was a moderately large amount of
heterogeneity between studies (P = 0.003, I2 = 65.6%).
No significant evidence for publication bias was observed
using the Egger test (P = 0.72), however, it should be
noted that there were only nine study estimates included
in the test, which can result in low power to detect asymmetry. Likewise, no clear association was present with
survival of local (stage I or II) or advanced stage patients
(stage III or IV), the latter which had a relatively high
degree of heterogeneity between studies (Fig. 2).
Since LCS6 is a functional SNP in the Let-7-binding
site of KRAS that impacts KRAS expression, and KRAS
overexpression has been accepted in clinical practice as a
negative predictive biomarker for patients treated with
anti-EGFR therapy [39], we performed a subgroup analysis on metastatic colorectal cancer patients treated with
anti-EGFR therapies (four studies with an aggregate of
643 patients). However, despite the reported potential of
the LCS6 SNP to elevate KRAS expression [14], no association was observed (Fig. 3). Contrary to our efforts to
reduce between-study heterogeneity through subgroup
analysis restricted to metastatic colorectal cancer patients
with metastatic disease treated with anti-EGFR therapies,
a high degree of heterogeneity remained (P = 0.01,
I2 = 73.3%). Likewise, no association was observed after
further restriction to KRAS wild-type metastatic colorectal
cancer patients (Fig. S1); albeit somewhat attenuated, a
moderate degree of heterogeneity remained between studies (I2 = 44.0%).
Progression-free survival
We also found no significant association between KRASLCS6 genotype and progression-free survival (Fig. 4),
which was reported only by the four studies that
restricted enrollment to metastatic colorectal patients
(with an aggregate of 672 patients) [19, 20, 23, 26], with
a moderate degree of heterogeneity between studies
(P = 0.07, I2 = 54.0%). No significant evidence for publication bias was observed using the Egger test (P = 0.24),
although this should be interpreted with caution since
there were only five study estimates included in the test
(separate HR estimates were included in the meta-analysis
by anti-EFGR treatment status for the study by Kjersem
et al. [20]), which could adversely impact power to detect
asymmetry. No significant association was observed in the
subgroup analysis restricted to KRAS wild-type patients
(Fig. S2).

Overall survival
We did not find any relationship between KRAS-LCS6
genotype and overall survival when considering all colorectal cancer patients regardless of treatment and stage
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Discussion
After reviewing and summarizing the literature, we found
no clear association between the KRAS-LCS6 genotype

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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2011
2011
2011
2012
2012
2010

2011

2012

2013

Smits et al. [24]
Smits et al. [24]
Smits et al. [24]
Ryan et al. [22]
Ryan et al. [22]
Graziano et al. [19]

Zhang et al. [25]

Kjersem et al. [20]

Sebio et al. [23]

Stage IV
(mCRC)
Stage IV
(mCRC)

Stage IV
(mCRC)

Stage I/II
Stage III
Stage IV
Stage I/II
Stage III/IV
Stage IV
(mCRC)

Stage
(86%)
(81%)
(78%)
(83%)
(87%)
(72%)

72 (78%)

451 (84%)

62 (83%)

326
137
54
88
109
87

TT
(14%)
(19%)
(22%)
(17%)
(13%)
(28%)

20 (22%)

84 (16%)

13 (17%)

53
33
15
18
16
34

TG/GG

Spain

Norway

USA

Netherlands
Netherlands
Netherlands
USA
USA
Italy

Country
Treatment not specified
Treatment not specified
Treatment not specified
Treated primarily with 5-FU
Treated primarily with 5-FU
Chemorefractory mCRC
treated with
cetuximab + irinotecan
Chemorefractory mCRC
treated with cetuximab
(montherapy)
Treated with 5-FU and
oxaliplatin  cetuximab
Chemorefractory mCRC
treated with
cetuximab + (irinotecan OR
oxaliplatin) or panitumumab
(monotherapy)

Patients/treatment

OS, PFS

OS, PFS

2004–2012

2005–2009

2002–2005

1986–1994
1986–1994
1986–1994
1992–2003
1992–2003
2005–2008

DS-S1
DS-S1
DS-S1
OS
OS
OS, PFS

OS, PFS

Recruitment
period

Primary
outcomes

60.0

60.4–63.83

18.62

47.12

66.0

68.0
67.5
68.5
n/a
n/a
65.0

>60
>60
52.82
>60
>60
35.02

43.0

Median
age (years)

Maximum
follow-up
(months)

64%

60%

49%

53%
57%
48%
n/a
n/a
54%

% Male

E

E

EA, AA,
AsA, O

E
E
E
AA, EA
AA, EA
E

Races/
ethnicities

mCRC, metastatic colorectal cancer; 5-FU, 5-fluorouracil; DS-S, disease-specific survival; OS, overall survival; PFS, progression-free survival; E, European; AA, African American; EA, European
American; AsA, Asian American; O, other race or ethnicity.
1
Treated as overall survival in the meta-analyses.
2
Approximated from the Kaplan–Meier survivor function provided in the manuscript.
3
Study reports median age by study arm and LCS6 genotype.

Year

Study

KRAS-LCS6 Genotype, n (%)

Table 1. Characteristics of studies included in the meta-analyses.
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(A)

(B)

(C)

Figure 2. Summary estimates for the association between the KRAS-LCS6 polymorphism (rs61764370) and overall survival for patients with all
stages of colorectal cancer. (A) Forest plot stratified by cancer stage; (B) summary of survival curve for patients with all stages; (C) summary of
survival curve for advanced stage colorectal cancer patients. The study by Sebio et al. [23] was not included in the estimation of the meta-survival
curve since the manuscript did not present a survival curve. mCRC, metastatic colorectal cancer.

and overall or progression-free survival among colorectal
cancer patients, even after conducting subgroup analysis
by stage and anti-EGFR treatment status. These results
suggest that KRAS-LCS6 genotype is an insufficient
predictor of outcome by itself and they provide insight
into the conflicting body of literature surrounding clinical
utility of KRAS-LCS6 genetic testing in the clinical
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management of this disease, demonstrating the complexity of colorectal cancer and the need for additional, more
complex batteries of molecular markers to optimize therapeutic regimens guided by precision medicine approaches.
Notwithstanding our best efforts to reduce betweenstudy heterogeneity through subgroup analyses, a substantial amount of heterogeneity remained. The prospective

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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(A)

(B)

Figure 3. Summary estimates for the association between the KRAS-LCS6 polymorphism (rs61764370) and overall survival for patients with
metastatic colorectal cancer. (A) Forest plot stratified by anti-EGFR treatment status; (B) summary of overall survival curve for patients with
metastatic colorectal cancer. The study by Sebio et al. [23] was not included in the estimation of the meta-survival curve since the manuscript did
not present a survival curve. EGFR, epidermal growth factor receptor; mono, monotherapy; Nordic FLOX, bolus 5-fluorouracil/folinic acid and
oxaliplatin.

nature of the studies included in the meta-analysis reduces
the risk of bias among the individual studies and no publication bias was observed across studies. However, even
after restricting to studies of metastatic colorectal cancer
patients treated with anti-EGFR therapies, heterogeneity
remained, suggesting a possible important role of concomitant treatments. Although these four studies [19, 20, 23, 26]
had in common the use of anti-EGFR therapy, most commonly cetuximab, one study also included patients treated

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

with panitumumab. Furthermore, not all studies were
restricted to patients lacking somatic KRAS or BRAF mutations, and there was broad variability in terms of combination therapy used (if any), including anti-metabolites
(5-fluorouracil), platinum-based cross-linking agents (oxaliplatin), or topoisomerase inhibitors (irinotecan). This
indicates a need for additional in-depth treatment-modality-specific research into the impact of this disease in
patients free of somatic KRAS and BRAF mutations.
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(A)

(B)

Figure 4. Summary estimates for the association between the KRAS-LCS6 polymorphism (rs61764370) and progression-free survival for patients
with metastatic colorectal cancer. (A) Forest plot stratified by anti-EGFR treatment status; (B) summary of progression-free survival curve for
patients with metastatic colorectal cancer. The study by Sebio et al. [23] was not included in the estimation of the meta-survival curve since the
manuscript did not present a survival curve. EGFR, epidermal growth factor receptor; mono, monotherapy; Nordic FLOX, bolus 5-fluorouracil/
folinic acid and oxaliplatin.

Strengths of this meta-analysis include the prospective
nature of the reviewed studies and our ability to discriminate by stage at diagnosis, including patients with
advanced metastatic disease. The aggregate nature of this
meta-analysis, which greatly enhanced the sample size in
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our analyses, is another major strength of this study. Post
hoc calculations indicate that we had ample statistical
power to detect clinically relevant associations, with ≥80%
power to detect an HR >1.19 and 1.22 for our overall
and progression-free survival, respectively, and ≥1.26 for

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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each respective outcome in our analyses that were
restricted to anti-EGFR treated patients. Furthermore, our
adherence to the PRISMA statement guidelines [40]
underscore the systematic nature of our comprehensive
review and meta-analysis and enhance the transparency of
our methods and results. Additionally, we were able to
estimate survival curves for all but one of the studies
included in our meta-analysis, providing a visual companion to the summary hazard ratio estimates allowing
for better interpretation of the results. However, there
were also several limitations to the study. Hazard ratio
estimates were only directly available for three of the six
studies included in the meta-analyses and therefore indirect estimation methods had to be applied, which may
not exactly reflect the true measured effect, although it is
doubtfully based on the data that this could have
impacted the overall lack of significant associations
observed in this meta-analysis. Furthermore, as is the case
with most meta-analyses, the summary estimates are
based on aggregate results in published literature, rather
than individual-level patient data, which could potentially
introduce bias. However, in order for confounding to
impact study estimates, KRAS-LCS6 genotype would have
to be associated with another unaccounted factor that
also impacts prognosis, which although conceptually
plausible, is unlikely. Additionally, as the patients
included in the published studies were predominantly
Caucasian, which is the population with the highest variant allele frequency (~0.15) based on estimates provided
by dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and Allele
Frequency Database (ALFRED; http://alfred.med.yale.edu/
), it is unclear how these findings generalize to patients of
other races/ethnicities, among whom the variant allele is
much less common.
Our results show that KRAS-LCS6 genotype alone is
not a meaningful predictor of outcome for colorectal cancer patients as a whole or for those with metastatic disease treated with anti-EGFR therapy. However, as several
of the studies included in this review reported significant
associations with outcome in well-conducted, prospective
studies, it arouses the possibility that the prognostic value
of KRAS-LCS6 genotype may be largely dependent on the
combination therapy (if any) used in conjunction with
the anti-EGFR treatment. Additional future studies are
required to determine the effectiveness of KRAS-LCS6
genotype in the prognostication of patients treated with
specific anti-EGFR mono and combination therapy regimens.
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Additional Supporting Information may be found in the
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Figure S1. Forest plots for the subgroup analyses of the
association between KRAS-LCS6 and overall survival for
patients lacking a somatic KRAS mutation.
Figure S2. Forest plots for the subgroup analyses of the
association between KRAS-LCS6 and progression-free survival for patients lacking a somatic KRAS mutation.
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